News

A new method uses a novel catalyst and inexpensive fluoride salts to modify the most common chemical bonds—opening doors to new medicines and improved medical imaging.

A Scripps Research-led study resolves the challenge of synthesizing saxitoxin, paving the way for new possibilities in pain management.

New findings from Scripps Research reveal how certain tumors survive DNA damage—and point to a strategy for targeting them.

New AI system helps scientists rapidly pinpoint the most promising paths to an HIV vaccine.

Molecular insights could lead to improved labor and pain treatments.

The recognized researchers encompass various areas including chemistry, microbiology, immunology, biochemistry and more.

Study reveals how sugar-protein interactions are critical for the placenta during early pregnancy, shedding light on complications like preeclampsia and restricted fetal growth.

Finance and biomedical leaders bring decades of experience in investment strategy and drug development.

The funding will support a multidisciplinary collaboration of four Scripps Research scientists to identify more effective vaccines to treat HIV.

Study will investigate whether a GIP/GLP-1 dual receptor agonist, currently approved for type 2 diabetes, obesity and obstructive sleep apnea, can reduce symptoms of long COVID.

Support from the National Institute of Diabetes and Digestive and Kidney Diseases will help reveal how a newly discovered rare cell impacts the autoimmune disease.

The California Institute for Regenerative Medicine (CIRM) grant supports the development of a new technology designed to restore normal gene function in select neurodevelopmental disorders.

An NIH-backed effort aims to decode how the nervous system monitors internal organs.

New findings reveal how specialized cells shield the pancreas from autoimmune attack, providing new therapeutic strategies for type 1 diabetes.

The novel computer method to encode synthetic protein sequences within cell lipid environments offers insights into how membrane proteins fold and function, critical to understanding disease.

Shimon Sakaguchi is honored for his revolutionary discovery of regulatory T cells—revealing how “immune tolerance” impacts autoimmune diseases, cancer and more.

Associate Professor Xin Jin selected for up to two five-year terms, receiving up to $8.6 million over 10 years to support neuroscience and genomic research.

Study by Scripps Research scientists shows how the brain learns to seek alcohol for relief, not just pleasurable effects, in an animal model.

Scripps Research study shows how smartwatch and fitness tracker data align with hormonal changes, offering the potential for early detection of complications.

Scripps Research breakthrough reduces antibody discovery time from weeks to hours, potentially revolutionizing pandemic response and therapeutic development.

Findings from Scripps Research reveal promising drug targets with potential to block coronaviruses at multiple stages of infection—even across different strains.

Study led by Scripps Research, Texas A&M and additional institutions highlights that the world’s deadliest infectious disease needs novel, effective antibiotics.

A new platform developed at Scripps Research enables fast, scalable protein evolution—opening the door to new therapies and diagnostics, and to predicting resistance mutations across many disease areas.

Phase 3 trial results from Scripps Research and collaborators helped support FDA approval of ENCELTO, the first cell-based therapy for a neurodegenerative retinal condition called MacTel.